Published Date: 15 Nov 2024
Possible guidance for use of adjuvant immunotherapy in high-risk, non-metastatic disease
Read Full NewsA new phase 2 study presented at AES 2025 showed that stiripentol may reduce seizure burden in patients with Lennox-Gastaut syndrome.
Sharon Hesterlee, PhD, President and CEO of the Muscular Dystrophy Association, discussed the 2026 MDA Conference, the significance of its keynote speaker, and the evolving therapeutic landscape in neuromuscular medicine.
A new study presented at AES 2025 examined factors linked to declining surgery for pediatric drug-resistant epilepsy and highlighted variability in candidate selection across centers.
The positive interim findings research represents the first clinical data for ETX101, an investigational cell-type-selective gene therapy, and the first potential one-time disease-modifying treatment for Dravet syndrome.
Lingdolinurad Demonstrates Dose-Dependent Serum Uric Acid Reductions
House Dust Mite SLIT Tablet Well Tolerated in Children With Allergic Asthma
AI in Dermatology: Discussing Downsides to the Adoption of Artificial Intelligence
1.
finding fresh approaches to treating diffuse midline gliomas.
2.
Research finds low uptake of supportive care at the end-of-life for patients with advanced cancer
3.
According to JAMA, statin use may increase cancer-related survival in breast cancer patients.
4.
Frontline Mosunetuzumab Shows High Response Rates in Follicular Lymphoma
5.
Getting More Done With Less Blood.
1.
Unlocking the Mystery of Glanzmann Thrombasthenia: A New Hope for Patients
2.
Navigating the Unknown: A Guide to Living With Hurthle Cell Thyroid Cancer
3.
Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain
4.
Genetic Screening: A Game Changer in Cancer Prevention
5.
Ethics of Experimental Oncology: Case Study on Autonomy, Consent & Decision-Making
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma
2.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
3.
Navigating the Complexities of Ph Negative ALL - Part X
4.
Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation